Key statistics dashboard for PureTech Health plc (PRTC). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others.
Stock Data
| Price | $17.38 |
| Market Cap | $4.2B |
| Enterprise Value | $4.00B |
| Beta | 0.71 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.60 |
| Price / Book | 0.13 |
| P/S | 910.18 |
| EV/EBITDA | -42.07 |
| EV/Sales | 859.73 |
| EV/FCF | -47.12 |
| P/FCF | -49.88 |
| Earnings Yield | -261.03% |
| FCF Yield | -2.00% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -471.15% |
| EBIT Margin | -2115.43% |
| EBITDA Margin | -2043.54% |
| Operating Margin | -2115.41% |
| Net Margin | -2355.50% |
| Return on Equity | -31.83% |
| Return on Assets | -20.48% |
| Return on Invested Capital | -19.64% |
| Return on Capital Employed | -20.13% |
Financial Health
| Current Ratio | 6.59 |
| Quick Ratio | 6.59 |
| Cash Ratio | 5.49 |
| Debt / Equity | 0.06 |
| Debt / Assets | 3.66% |
| Net Debt / EBITDA | 2.47 |
| Interest Coverage | -2.16 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 0.25 |
Per-Share Data
| Revenue per share | 1.93 |
| Book Value per share | 126.65 |
| Cash per share | 115.55 |
| FCF per share | -35.14 |
| Tangible Book Value per share | 126.40 |
| Dividend per share | 0.00 |
Related companies: CLYM · GNTA · INBX · IVA · KROS · SLN · TARS
Explore sector: Healthcare · Biotechnology
More sections of PRTC: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks